These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38138538)

  • 1. Structure-Activity Studies on Bis-Sulfonamide SHIP1 Activators.
    Meyer ST; Fernandes S; Anderson RE; Pacherille A; Toms B; Kerr WG; Chisholm JD
    Molecules; 2023 Dec; 28(24):. PubMed ID: 38138538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of inositol 5-phosphatase activity by the C2 domain of SHIP1 and SHIP2.
    Bradshaw WJ; Kennedy EC; Moreira T; Smith LA; Chalk R; Katis VL; Benesch JLP; Brennan PE; Murphy EJ; Gileadi O
    Structure; 2024 Apr; 32(4):453-466.e6. PubMed ID: 38309262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SH2 domains of inositol polyphosphate 5-phosphatases SHIP1 and SHIP2 have similar ligand specificity but different binding kinetics.
    Zhang Y; Wavreille AS; Kunys AR; Pei D
    Biochemistry; 2009 Nov; 48(46):11075-83. PubMed ID: 19839650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer.
    Fuhler GM; Brooks R; Toms B; Iyer S; Gengo EA; Park MY; Gumbleton M; Viernes DR; Chisholm JD; Kerr WG
    Mol Med; 2012 Feb; 18(1):65-75. PubMed ID: 22033675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells.
    Wisniewski D; Strife A; Swendeman S; Erdjument-Bromage H; Geromanos S; Kavanaugh WM; Tempst P; Clarkson B
    Blood; 1999 Apr; 93(8):2707-20. PubMed ID: 10194451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells.
    Ong CJ; Ming-Lum A; Nodwell M; Ghanipour A; Yang L; Williams DE; Kim J; Demirjian L; Qasimi P; Ruschmann J; Cao LP; Ma K; Chung SW; Duronio V; Andersen RJ; Krystal G; Mui AL
    Blood; 2007 Sep; 110(6):1942-9. PubMed ID: 17502453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The two SH2-domain-containing inositol 5-phosphatases SHIP1 and SHIP2 are coexpressed in human T lymphocytes.
    Bruyns C; Pesesse X; Moreau C; Blero D; Erneux C
    Biol Chem; 1999; 380(7-8):969-74. PubMed ID: 10494849
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Olufunmilayo EO; Holsinger RMD
    Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo.
    Stenton GR; Mackenzie LF; Tam P; Cross JL; Harwig C; Raymond J; Toews J; Wu J; Ogden N; MacRury T; Szabo C
    Br J Pharmacol; 2013 Mar; 168(6):1506-18. PubMed ID: 23121445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late-onset Alzheimer's disease.
    Jesudason CD; Mason ER; Chu S; Oblak AL; Javens-Wolfe J; Moussaif M; Durst G; Hipskind P; Beck DE; Dong J; Amarasinghe O; Zhang ZY; Hamdani AK; Singhal K; Mesecar AD; Souza S; Jacobson M; Salvo JD; Soni DM; Kandasamy M; Masters AR; Quinney SK; Doolen S; Huhe H; Rizzo SJS; Lamb BT; Palkowitz AD; Richardson TI
    Alzheimers Dement (N Y); 2023; 9(4):e12429. PubMed ID: 38023622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling.
    Brauer H; Strauss J; Wegner W; Müller-Tidow C; Horstmann M; Jücker M
    Cell Signal; 2012 Nov; 24(11):2095-101. PubMed ID: 22820502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo.
    Stenton GR; Mackenzie LF; Tam P; Cross JL; Harwig C; Raymond J; Toews J; Chernoff D; MacRury T; Szabo C
    Br J Pharmacol; 2013 Mar; 168(6):1519-29. PubMed ID: 23121409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the Src homology 2 domain-containing inositol 5'-phosphatase (SHIP1) by the cyclic AMP-dependent protein kinase.
    Zhang J; Walk SF; Ravichandran KS; Garrison JC
    J Biol Chem; 2009 Jul; 284(30):20070-8. PubMed ID: 19494109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced expression and activity of patient-derived SHIP1 phosphatase domain mutants.
    Ehm P; Nelson N; Giehler S; Schaks M; Bettin B; Kirchmair J; Jücker M
    Cell Signal; 2023 Jan; 101():110485. PubMed ID: 36208705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism.
    An H; Xu H; Zhang M; Zhou J; Feng T; Qian C; Qi R; Cao X
    Blood; 2005 Jun; 105(12):4685-92. PubMed ID: 15701712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and development of small molecule SHIP phosphatase modulators.
    Viernes DR; Choi LB; Kerr WG; Chisholm JD
    Med Res Rev; 2014 Jul; 34(4):795-824. PubMed ID: 24302498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A key role for the phosphorylation of Ser440 by the cyclic AMP-dependent protein kinase in regulating the activity of the Src homology 2 domain-containing Inositol 5'-phosphatase (SHIP1).
    Zhang J; Ravichandran KS; Garrison JC
    J Biol Chem; 2010 Nov; 285(45):34839-49. PubMed ID: 20810657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SH2-containing inositol 5-phosphatases 1 and 2 in blood platelets: their interactions and roles in the control of phosphatidylinositol 3,4,5-trisphosphate levels.
    Giuriato S; Pesesse X; Bodin S; Sasaki T; Viala C; Marion E; Penninger J; Schurmans S; Erneux C; Payrastre B
    Biochem J; 2003 Nov; 376(Pt 1):199-207. PubMed ID: 12885297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel SHIP1 agonist that promotes degradation of lipid-laden phagocytic cargo by microglia.
    Pedicone C; Fernandes S; Matera A; Meyer ST; Loh S; Ha JH; Bernard D; Chisholm JD; Paolicelli RC; Kerr WG
    iScience; 2022 Apr; 25(4):104170. PubMed ID: 35465359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SH2 domain containing inositol 5-phosphatase SHIP2 displays phosphatidylinositol 3,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activity.
    Pesesse X; Moreau C; Drayer AL; Woscholski R; Parker P; Erneux C
    FEBS Lett; 1998 Oct; 437(3):301-3. PubMed ID: 9824312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.